TY - JOUR
T1 - Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma
AU - Welch, Jennifer J.G.
AU - Schwartz, Cindy L.
AU - Higman, Meghan
AU - Chen, Lu
AU - Buxton, Allen
AU - Kanakry, Jennifer A.
AU - Kahwash, Samir B.
AU - Hutchison, Robert E.
AU - Friedman, Debra L.
AU - Ambinder, Richard F.
N1 - Funding Information:
This work was supported by National Institutes of Health, National Cancer Institute grants CA95423, P50CA96888, and R21CA188824 (R.F.A.), CA98543 (Children’s Oncology Group), and U24 CA114766.
Funding Information:
This work was supported by National Institutes of Health, National Cancer Institute grants CA95423, P50CA96888, and R21CA188824 (R.F.A.), CA98543 (Children?s Oncology Group), and U24 CA114766.
Publisher Copyright:
© 2017 American Society of Hematology. All rights reserved.
PY - 2017/4/25
Y1 - 2017/4/25
N2 - Assay of cell-free DNA in blood offers an approach to assessment of tumor DNA. We sought to determine whether Epstein-Barr virus (EBV) DNA in cell-free blood is also a good surrogate for the presence of tumor DNA in children with Hodgkin lymphoma, as it is in adults, and whether it correlates with pediatric outcomes. Pediatric patients enrolled in a Children’s Oncology Group trial (AHOD0031) were studied at baseline and at 8 days after the initiation of treatment. At baseline, EBV DNA in cell-free blood correlated with the presence of EBV in tumor, and EBV DNA 8 days after the initiation of therapy predicted inferior event-free survival. EBV DNA in cell-free blood warrants further investigation as a marker of inadequate tumor response in Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00025259.
AB - Assay of cell-free DNA in blood offers an approach to assessment of tumor DNA. We sought to determine whether Epstein-Barr virus (EBV) DNA in cell-free blood is also a good surrogate for the presence of tumor DNA in children with Hodgkin lymphoma, as it is in adults, and whether it correlates with pediatric outcomes. Pediatric patients enrolled in a Children’s Oncology Group trial (AHOD0031) were studied at baseline and at 8 days after the initiation of treatment. At baseline, EBV DNA in cell-free blood correlated with the presence of EBV in tumor, and EBV DNA 8 days after the initiation of therapy predicted inferior event-free survival. EBV DNA in cell-free blood warrants further investigation as a marker of inadequate tumor response in Hodgkin lymphoma. This trial was registered at www.clinicaltrials.gov as #NCT00025259.
UR - http://www.scopus.com/inward/record.url?scp=85040967527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040967527&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2016002618
DO - 10.1182/bloodadvances.2016002618
M3 - Article
AN - SCOPUS:85040967527
SN - 2473-9529
VL - 1
SP - 681
EP - 684
JO - Blood Advances
JF - Blood Advances
IS - 11
ER -